Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.
All articles by Jody A. Charnow
First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.
Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.
Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.
Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.
Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.
Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
Postoperative radiation therapy with adjuvant chemotherapy prolonged disease-free survival and overall survival in patients with locally advanced urothelial carcinoma.
Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
In a study of patients receiving non-surgical treatment for localized upper tract urothelial carcinoma, radiation or chemotherapy provided no overall survival benefit.
Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer
Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.
Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer
Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.
Next post in Genitourinary Cancers Symposium 2019
